If I said the company name Phosphagenics to you, would it ring a bell? Unless you really know the Life Sciences sector of the ASX really well, probably not. What if I said to you that this was the Melbourne-based company where, in 2013, it was revealed that then CEO... Show More
Last week I published a report on a great Life Sciences company out of Singapore called Invitrocue. Singapore is one of the finest places a global traveler could find to do Life Sciences, ranking probably the seventh most-productive Life Sciences jurisdiction on the planet in terms of the amount of... Show More
Often in Life Sciences people speak of the 'Holy Grail' as something that everyone in a particular field is looking for and will be very pleased when it is found. It's an unusual term to use given that most people in Life Sciences either aren't Christian or aren't in touch... Show More
One of the more impressive re-brandings of a Life Science company that I've seen in recent years is Kazia Therapeutics, formerly Novogen. This company changed its name in late 2017 to reflect the acquisition from Genentech of an impressive new lead compound called GDC-0084, for the treatment of glioblastoma. We... Show More
Every now and then when people ask me about building a portfolio of Life Science companies, I tell them that having a regenerative medicine stock in the portfolio is probably a good idea because we're going into a boom for that field globally. In July last year we at NDF... Show More
Just over eighteen months ago, in July 2016, I published an article headlined 'The Coming Boom in Life Sciences, Down Under' in which I suggested that Australia was on the way to a boom for its biotech and medical device sector. I argued that all the elements of that coming... Show More
Some of the greatest healthcare plays I know involve a new product that is not only safe and effective but replace a current treatment modality best described as 'brutal'. AirXpanders (ASX: AXP), a >A$270m company which went public on ASX in 2015, is a great example. This company's AeroForm technology... Show More
If you've looked at the Life Sciences sector in Australia any time in the last ten years you would likely have come across Starpharma (ASX: SPL), now a >A$250m company. That's because of Starpharma's 'VivaGel'. As an anti-microbial polymer coating for condoms VivaGel is genius - the statistics on condom... Show More
